[1]
|
Pringsheim, T., Jette, N., Frolkis, A. and Steeves, T.D. (2014) The Prevalence of Parkinson’s Disease: A Systematic Re-view and Meta-Analysis. Movement Disorders, 29, 1583-1590. https://doi.org/10.1002/mds.25945
|
[2]
|
Parkinson, J. (2002) An Essay on the Shaking Palsy. Journal of Neuropsychiatry and Clinical Neurosciences, 14, 223-236. https://doi.org/10.1176/jnp.14.2.223
|
[3]
|
Allegri, R.F., Bartoloni, L. and Sica, R.E. (2016) History of the Depart-ment of Neurology at the University of Buenos Aires (1887-2007). Vertex, 27, 306-318.
|
[4]
|
Baldereschi, M., Di, C.A., Rocca, W.A., Vanni, P., Maggi, S., Perissinotto, E., et al. (2000) Parkinson’s Disease and Parkinsonism in a Longitudi-nal Study: Two-Fold Higher Incidence in Men. Neurology, 55, 1358-1363.
https://doi.org/10.1212/WNL.55.9.1358
|
[5]
|
Jankovic, J. (2008) Parkinson’s Disease: Clinical Features and Diag-nosis. Journal of Neurology Neurosurgery & Psychiatry, 79, 368-376. https://doi.org/10.1136/jnnp.2007.131045
|
[6]
|
Halliday, G.M., Holton, J.L., Revesz, T. and Dickson, D.W. (2011) Neuropathology Underlying Clinical Variability in Patients with Synucleinopathies. Acta Neuropathologica, 122, 187-204. https://doi.org/10.1007/s00401-011-0852-9
|
[7]
|
Damier, P., Hirsch, E.C., Agid, Y. and Graybiel, A.M. (1999) The Substantia Nigra of the Human Brain. II. Patterns of Loss of Dopamine-Containing Neurons in Parkinson’s Disease. Brain, 122, 1437-1448.
https://doi.org/10.1093/brain/122.8.1437
|
[8]
|
Dijkstra, A.A., Voorn, P., Berendse, H.W., Groenewegen, H.J., Rozemuller, A.J. and van de Berg, W.D. (2014) Stage-Dependent Nigral Neuronal Loss in Incidental Lewy Body and Parkinson’s Disease. Movement Disorders, 29, 1244-1251. https://doi.org/10.1002/mds.25952
|
[9]
|
Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A.I., Jansen Steur, E.N.H. and Braak, E. (2003) Staging of Brain Pathology Related to Sporadic Parkinson’s Disease. Neurobiology of Aging, 24, 197-211.
https://doi.org/10.1016/S0197-4580(02)00065-9
|
[10]
|
Iacono, D., Geraci-Erck, M., Rabin, M.L., Adler, C.H., Ser-rano, G., Beach, T.G., et al. (2015) Parkinson Disease and Incidental Lewy Body Disease: Just a Question of Time? Neurology, 85, 1670-169.
https://doi.org/10.1212/WNL.0000000000002102
|
[11]
|
Chaudhuri, K.R. and Schapira, A.H. (2009) Non-Motor Symptoms of Parkinson’s Disease: Dopaminergic Pathophysiology and Treatment. Lancet Neurology, 8, 464-474. https://doi.org/10.1016/S1474-4422(09)70068-7
|
[12]
|
PD MED Collaborative Group (2014) Long-Term Effec-tiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinson’s Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial. Lancet, 384, 1196-1205. https://doi.org/10.1016/S0140-6736(14)60683-8
|
[13]
|
Mahlknecht, P., Gasperi, A., Willeit, P., Kiechl, S., Stockner, H., Willeit, J., et al. (2016) Prodromal Parkinson’s Disease as Defined per MDS Research Criteria in the General Elderly Community. Movement Disorders, 31, 1405-1408.
https://doi.org/10.1002/mds.26674
|
[14]
|
Xu, Q., Park, Y., Huang, X., Hollenbeck, A., Blair, A., Schatzkin, A., et al. (2010) Physical Activities and Future Risk of Parkinson Disease. Neurology, 75, 341-348. https://doi.org/10.1212/WNL.0b013e3181ea1597
|
[15]
|
Yang, F., Trolle Lagerros, Y., Bellocco, R., Adami, H.-O., Fang, F., Pedersen, N.L., et al. (2014) Physical Activity and Risk of Parkinson’s Disease in the Swedish National March Cohort. Brain, 138, 269-275.
https://doi.org/10.1093/brain/awu323
|
[16]
|
Van Den Eeden, S.K., Tanner, C.M., Bernstein, A.L., Fross, R.D., Leimpeter, A., Bloch, D.A., et al. (2003) Incidence of Parkinson’s Disease: Variation by Age, Gender, and Race/Ethnicity. American Journal of Epidemiology, 157, 1015-1022.
https://doi.org/10.1093/aje/kwg068
|
[17]
|
Pinter, B., Diemzangerl, A., Wenning, G.K., Scherfler, C., Oberaigner, W., Seppi, K., et al. (2015) Mortality in Parkinson’s Disease: A 38-Year Follow-Up Study. Movement Disorders, 30, 819-825. https://doi.org/10.1002/mds.26060
|
[18]
|
Gjerstad, M.D., Wentzel-Larsen, T., Aarsland, D. and Larsen, J.P. (2007) Insomnia in Parkinson’s Disease: Frequency and Progression over Time. Journal of Neurology, Neurosur-gery, and Psychiatry, 78, 476-479.
https://doi.org/10.1136/jnnp.2006.100370
|
[19]
|
Morens, D.M., Davis, J.W., Grandinetti, A., Ross, G.W., Popper, J.S. and White, L.R. (1996) Epidemiologic Observations on Parkinson’s Disease Incidence and Mortality in a Prospec-tive Study of Middle-Aged Men. Neurology, 46, 1044-1050.
https://doi.org/10.1212/WNL.46.4.1044
|
[20]
|
Payami, H. and Zareparsi, S. (1973) Epidemiology of Parkinson’s Disease. Lancet Neurology, 66, 202-203.
|
[21]
|
Xiong, N., Long, X., Xiong, J., Jia, M., Chen, C., Huang, J., et al. (2012) Mitochondrial Complex I Inhibitor Rotenone-Induced Toxicity and Its Potential Mechanisms in Parkinson’s Disease Models. Critical Reviews in Toxicology, 42, 613-632. https://doi.org/10.3109/10408444.2012.680431
|
[22]
|
Ascherio, A. and Schwarzschild, M.A. (2016) The Epidemi-ology of Parkinson’s Disease: Risk Factors and Prevention. Lancet Neurology, 15, 1257-1272. https://doi.org/10.1016/S1474-4422(16)30230-7
|
[23]
|
Nalls, M.A., Pankratz, N., Lill, C.M., Do, C.B., Hernandez, D.G., Saad, M., et al. (2014) Large-Scale Meta-Analysis of Genome-Wide Association Data Identifies Six New Risk Loci for Parkinson’s Disease. Nature Genetics, 46, 989-993.
https://doi.org/10.1038/ng.3043
|
[24]
|
马敬红, 陈彪. 帕金森病患者发病年龄与临床异质性的回顾性分析[J]. 中国临床康复, 2005, 9(17): 10-12.
|
[25]
|
Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H.J. and Stefanis, L. (2011) Pathological Roles of α-Synuclein in Neurological Disorders. Lancet Neurology, 10, 1015-1025. https://doi.org/10.1016/S1474-4422(11)70213-7
|
[26]
|
Xilouri, M., Brekk, O.R. and Stefanis, L. (2013) Al-pha-Synuclein and Protein Degradation Systems: a Reciprocal Relationship. Molecular Neurobiology, 47, 537-551. https://doi.org/10.1007/s12035-012-8341-2
|
[27]
|
Chu, Y. and Kordower, J.H. (2007) Age-Associated Increases of α-Synuclein in Monkeys and Humans Are Associated with Nigrostriatal Dopamine Depletion: Is This the Target for Par-kinson’s Disease? Neurobiology of Disease, 25, 134-149.
https://doi.org/10.1016/j.nbd.2006.08.021
|
[28]
|
Buneeva, O.A. and Medvedev, A.E. (2011) Mitochondrial Dys-function in Parkinson’s Disease. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 5, 313-336. https://doi.org/10.1134/S1990750811040032
|
[29]
|
Devi, L., Raghavendran, V., Prabhu, B.M., Avadhani, N.G. and Anandatheerthavarada, H.K. (2008) Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain. Journal of Biological Chemistry, 283, 9089-9100. https://doi.org/10.1074/jbc.M710012200
|
[30]
|
Telford, J.E., Kilbride, S.M. and Davey, G.P. (2009) Complex I Is Rate-Limiting for Oxygen Consumption in the Nerve Terminal. Journal of Biological Chemistry, 284, 9109-9114. https://doi.org/10.1074/jbc.M809101200
|
[31]
|
Dias, V., Junn, E. and Mouradian, M.M. (2013) The Role of Oxida-tive Stress in Parkinson’s Disease. Journal of Parkinson’s Disease, 3, 461-491. https://doi.org/10.3233/JPD-130230
|
[32]
|
Di, N.M., Masciullo, M., Verrigni, D., Petrillo, S., Modoni, A., Rizzo, V., et al. (2016) DJ-1 Modulates Mitochondrial Response to Oxidative Stress: Clues from a Novel Diagnosis of PARK7. Clinical Genetics, 92, 18-25.
https://doi.org/10.1111/cge.12841
|
[33]
|
Guzman, J.N., Sanchez-Padilla, J., Wokosin, D., Kondapalli, J., Ilijic, E., Schumacker, P.T., et al. (2010) Oxidant Stress Evoked by Pacemaking in Dopaminergic Neurons Is Attenuated by DJ-1. Nature, 468, 696-700.
https://doi.org/10.1038/nature09536
|
[34]
|
Surmeier, D.J., Schumacker, P.T., Guzman, J.D., Ilijic, E., Yang, B. and Zampese, E. (2016) Calcium and Parkinson’s Disease. Biochemical & Biophysical Research Communications, 483, 1013-1019.
https://doi.org/10.1016/j.bbrc.2016.08.168
|
[35]
|
Moehle, M.S. and West, A.B. (2015) M1 and M2 Immune Acti-vation in Parkinson’s Disease: Foe and Ally? Neuroscience, 302, 59-73. https://doi.org/10.1016/j.neuroscience.2014.11.018
|
[36]
|
Ransohoff, R.M. (2016) How Neuroinflammation Con-tributes to Neurodegeneration. Science, 353, 777-783.
https://doi.org/10.1126/science.aag2590
|
[37]
|
Ma, B., Xu, L., Pan, X., Sun, L., Ding, J., Xie, C., et al. (2015) LRRK2 Modulates Microglial Activity through Regulation of Chemokine (C–X3–C) Receptor 1-Mediated Signaling Pathways. Human Molecular Genetics, 25, 3515-3523.
https://doi.org/10.1093/hmg/ddw194
|
[38]
|
Hirsch, E.C. and Hunot, S. (2009) Neuroinflammation in Parkinson’s Disease: A Target for Neuroprotection? Lancet Neurology, 8, 382-397. https://doi.org/10.1016/S1474-4422(09)70062-6
|
[39]
|
Gao, H.M., Kotzbauer, P.T., Uryu, K., Leight, S., Trojan-owski, J.Q. and Lee, V.M.-Y. (2008) Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminer-gic Neurodegeneration. Journal of Neuroscience, 28, 7687-7698.
https://doi.org/10.1523/JNEUROSCI.0143-07.2008
|
[40]
|
George, S. and Brundin, P. (2015) Immunotherapy in Parkinson’s Disease: Micromanaging α-Synuclein Aggregation. Journal of Parkinson’s Disease, 5, 413-424. https://doi.org/10.3233/JPD-150630
|
[41]
|
Oksanen, M., Lehtonen, S., Jaronen, M., Goldsteins, G., Hämäläinen, R.H. and Koistinaho, J. (2019) Astrocyte Alterations in Neurodegenerative Pathologies and Their Modeling in Human Induced Pluripotent Stem Cell Platforms. Cellular and Molecular Life Sciences, 76, 2739-2760. https://doi.org/10.1007/s00018-019-03111-7
|
[42]
|
Rocha, N.P., De Miranda, A.S. and Teixeira, A.L. (2015) In-sights into Neuroinflammation in Parkinson’s Disease: From Biomarkers to Anti-Inflammatory Based Therapies. BioMed Research International, 2015, Article ID: 628192.
https://doi.org/10.1155/2015/628192
|
[43]
|
Tang, Y. and Le, W. (2016) Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. Molecular Neurobiology, 53, 1181-1194. https://doi.org/10.1007/s12035-014-9070-5
|
[44]
|
Rojanathammanee, L., Murphy, E.J. and Combs, C.K. (2011) Expression of Mutant α-Synuclein Modulates Microglial Phenotype in Vitro. Journal of Neuroinflammation, 8, Article No. 44. https://doi.org/10.1186/1742-2094-8-44
|
[45]
|
Lewitt, P.A. and Fahn, S. (2016) Levodopa Therapy for Par-kinson Disease: A Look Backward and Forward. Neurology, 86, S3-S12. https://doi.org/10.1212/WNL.0000000000002509
|
[46]
|
Cenci, M.A. (2014) Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications. Frontiers in Neurology, 5, Ar-ticle No. 242. https://doi.org/10.3389/fneur.2014.00242
|
[47]
|
Ferreira, J.J., Lees, A., Rocha, J.F., Poewe, W., Rascol, O., Soares-da-Silva, P., et al. (2016) Opicapone as an Adjunct to Levodopa in Patients with Parkinson’s Disease and End-of-Dose Motor Fluctuations: A Randomised, Double-Blind, Controlled Trial. Lancet Neurology, 15, 154-165. https://doi.org/10.1016/S1474-4422(15)00336-1
|
[48]
|
Schapira, A.H. (2011) Monoamine Oxidase B Inhibitors for the Treatment of Parkinson’s Disease: A Review of Symptomatic and Potential Disease-Modifying Effects. CNS Drugs, 25, 1061-1071.
https://doi.org/10.2165/11596310-000000000-00000
|
[49]
|
Birkmayer, W., Riederer, P., Ambrozi, L. and Youdim, M.B.H. (1977) Implications of Combined Treatment with ‘Madopar’ and L-Deprenil in Parkinson’s Disease: A Long-Term Study. Lancet, 1, 439-443.
https://doi.org/10.1016/S0140-6736(77)91940-7
|
[50]
|
Connolly, B.S. and Lang, A.E. (2014) Pharmacological Treatment of Parkinson Disease: A Review. JAMA, 311, 1670-1683. https://doi.org/10.1001/jama.2014.3654
|
[51]
|
Jankovic, J. and Poewe, W. (2012) Therapies in Parkinson’s Disease. Current Opinion in Neurology, 25, 433-447.
https://doi.org/10.1097/WCO.0b013e3283542fc2
|
[52]
|
Limousin, P., Pollak, P., Benazzouz, A., Hoffmann, D., Le Bas, J.-F., Perret, J.E., et al. (1995) Effect on Parkinsonian Signs and Symptoms of Bilateral Subthalamic Nucleus Stim-ulation. Lancet, 345, 91-95.
https://doi.org/10.1016/S0140-6736(95)90062-4
|
[53]
|
Bronstein, J.M., Tagliati, M., Alterman, R.L., Lozano, A.M., Volkmann, J., Stefani, A., et al. (2011) Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Re-view of Key Issues. Archives of Neurology, 68, 165.
https://doi.org/10.1001/archneurol.2010.260
|
[54]
|
Voges, J., Hilker, R.B., Tzel, K., Kiening, K.L., Kloss, M., Kup-sch, A., et al. (2007) Thirty days Complication Rate Following Surgery Performed for Deep-Brain-Stimulation. Move-ment Disorders, 22, 1486-1489.
https://doi.org/10.1002/mds.21481
|
[55]
|
Li, W., Chen, S. and Li, J.Y. (2015) Human Induced Pluripotent Stem Cells in Parkinson’s Disease: A Novel Cell Source of Cell Therapy and Disease Modeling. Progress in Neurobiology, 134, 161-177.
https://doi.org/10.1016/j.pneurobio.2015.09.009
|
[56]
|
Chen, Z. (2015) Cell Therapy for Parkinson’s Disease: New Hope from Reprogramming Technologies. Aging & Disease, 6, 499-503. https://doi.org/10.14336/AD.2014.1201
|
[57]
|
Kim, D., Kim, C.H., Moon, J.I., Chung, Y.G., Chang, M.Y., Han, B.S., et al. (2009) Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins. Cell Stem Cell, 4, 472-476.
https://doi.org/10.1016/j.stem.2009.05.005
|
[58]
|
Kirkeby, A., Grealish, S., Wolf, D.A., Nelander, J., Wood, J., Lundblad, M., et al. (2012) Generation of Regionally Specified Neural Progenitors and Functional Neurons from Human Embryonic Stem Cells under Defined Conditions. Cell Reports, 1, 703-714. https://doi.org/10.1016/j.celrep.2012.04.009
|
[59]
|
Barker, R.A., Barrett, J., Mason, S.L. and Björklund, A. (2013) Fetal Dopaminergic Transplantation Trials and the Future of Neural Grafting in Parkinson’s Disease. Lancet Neurology, 12, 84-91.
https://doi.org/10.1016/S1474-4422(12)70295-8
|
[60]
|
Bloem, B.R., De Vries, N.M. and Ebersbach, G. (2015) Nonpharmacological Treatments for Patients with Parkinson’s Disease. Movement Disorders, 30, 1504-1520. https://doi.org/10.1002/mds.26363
|
[61]
|
Keus, S.H., Munneke, M., Nijkrake, M.J., Kwakkel, G. and Bloem, B.R. (2009) Physical Therapy in Parkinson’s Disease: Evolution and Future Challenges. Movement Disorders, 24, 1-14. https://doi.org/10.1002/mds.22141
|
[62]
|
Schrag, A., Jahanshahi, M. and Quinn, N. (2000) What Contributes to Quality of Life in Patients with Parkinson’s Disease? Journal of Neurology Neurosurgery & Psychiatry, 69, 308-312. https://doi.org/10.1136/jnnp.69.3.308
|
[63]
|
de Lau, L.M. and Breteler, M.M. (2006) Epidemiology of Parkinson Disease. Lancet Neurology, 5, 525-535.
https://doi.org/10.1016/s1474-4422(06)70471-9
|